Skip to main content

Table 1 Epidemiological and biological features in 67 patients with HCV and cryoglobulinemia

From: Hepatitis C-related cryoglobulinemic neuropathy: potential role of oxcarbazepine for pain control

Patients (total 67)

Features

Age (years)

50.4 ± 2.7

Sex ratio (M/F)

31/36

Apparent duration of disease (years)

4.1 ± 1.3

Albumin level (g/L)

39.7 ± 8.5

ALT (IU/L)

131.4 ± 16.7

Prothrombin time (%)

84.1 ± 12.2

Rheumatoid factors (n of pts. and %)

41/67 (61%)

Mean Cryoglobulinemia(g/L)

0.27 ± 0.8

Cryoglobulinemia type

 CGS TYPE II (n of pts. and %)

42/67 (64%)

 CGS TYPE III (n of pts. and %)

25/67 (36%)

 ANTI HCV Antibodies (n of pts. and %)

67/67 (100%)

 ANTI HBV Antibodies (n of pts. and %)

35/67 (52%)

 Anti HBC

30 (86%)

 HBsAg

5 (14.2)

 Anti HBS

30 (86%)

 HBeAG

0

 AntiHBe

0

 HCV RNA sequences in sera (n of pts. and %)

49/67 (73%)